Home > Resources > Whitepapers > CENTRAL & EASTERN EUROPE INVESTMENT OPPORTUNITIES IN PHARMACEUTICALS: RISK/REWARD ANALYSIS

CENTRAL & EASTERN EUROPE INVESTMENT OPPORTUNITIES IN PHARMACEUTICALS: RISK/REWARD ANALYSIS

Central & Eastern European markets are not considered amongst the most attractive globally for companies looking to launch innovative pharmaceuticals. The Czech Republic, which ranks first in Central & Eastern Europe, is ranked 22nd globally, whilst the region's second-ranked country, Poland is ranked 24th. Scoring in the Innovative Pharmaceuticals RRI favours larger markets with greater sales potential for multinationals. Indeed, neither market can compete with the high per-capita expenditure or absolute market size of the top global markets.

Spotlight

IDEA Pharma

Who? Pharma's leading experts in design thinking at phase II (path-to-market design) and positioning.

OTHER WHITEPAPERS

Considerations for migrating a drug product presentation from vial to pre-filled syringe

whitePaper | December 9, 2022

There is an upward trend for pharmaceutical companies to ask their contract development and manufacturing organisations (CDMO) to support the conversion.

Seize the digital momentum

whitePaper | January 23, 2023

Investments in biopharmaceutical (biopharma) research and development (R&D) continue to fuel innovation and shape the future of health. However, this year’s analysis demonstrates that despite impressive examples of innovative products the step-change in improved productivity seen in 2021 has not continued.

Drug Solubility and the Need for Speed

whitePaper | March 28, 2023

About 70% of new chemical entities (NCEs) are highly insoluble.1 It’s a fact that troubles small biotechnology companies and other drug manufacturers. Indeed, insoluble drugs present a wide range of challenges during development and, if not addressed, can ultimately render drugs ineffective in patients.

More Whitepapers